April 24, 2024
Skim if you can trim, buy if it will fly and sell if compelled as I BELIEVE a “wobble” IS coming.
Pre-open Indications: 6 Sell into Strength and 1 Negative Indications
Economic data releases and Fed responses usually send equities seesawing back and forth
Never leave an investor uninformed!
April 12, 2024
Watch on Netflix: “Bad Surgeon, Love under the Knife” a back story involving Harvard Apparatus RN (HRGN) … < www.hregen.com > formerly Biostage and Dr. Paolo Macchiarini formerly a world famous for his revolutionary stem cell-infused windpipe transplants.
“There's just one problem: His patients kept dying.”
Also answers the question of WHY Biostage (BSTG) and its former Chairman, CEO Biostage and current board member David Green of re-named company paid $5 million dollars to the VICTIM’s family and they are trying to re-test the artificial esophageal windpipe yet again at two (2) locations!
Are the remaining investors ready for the upcoming private placement of share increasing outstanding shares!
April 23, 2024
As indexes take a bullish tone ahead of key economic data and the beginning of sector earnings’ season
A 360-degree review of the who, why, when and what happened in the sector as the market and economics surround your portfolio’s defense or offence.
Last week, I wrote that I favor … caution over the next few weeks! Sticking to MY position.
Never leave an investor uninformed! A trusted source of factual reporting!
April 12, 2024
Watch on Netflix: “Bad Surgeon, Love under the Knife” a back story involving Harvard Apparatus RN (HRGN) … < www.hregen.com > formerly Biostage and Dr. Paolo Macchiarini formerly a world famous for his revolutionary stem cell-infused windpipe transplants. “There's just one problem: His patients kept dying.” Also answers the question of WHY Biostage (BSTG) and its former Chairman, CEO Biostage and current board member David Green of re-named company paid $5 million dollars to the VICTIM’s family and they are trying to re-test the artificial esophageal windpipe yet again at two (2) locations! Are the remaining investors ready for the upcoming private placement of share increasing outstanding shares!
April 2, 2024
A scorecard of earnings releases of covered companies - The current LPS (loss per share) or net income, cash positions i.e. "runways" is a reflection of this universe's investing "status". 30 of 35 covered released to date
March 22, 2024
SGMO dived $0.1465 to $08238 or -15.098% And pre-funded warrants of 3,809,523 shares of common stock, together with accompanying warrants to purchase up to an aggregate of 28,571,428 shares of common stock priced at $0.83 Gross proceeds $24 M possible Barclays and Cantor are acting as placement agents for the offering
© 2024 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
